<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03924661</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10237</org_study_id>
    <nct_id>NCT03924661</nct_id>
  </id_info>
  <brief_title>SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy</brief_title>
  <official_title>A Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This PAS is an observational, non-randomized, multi-center, single arm, clinical study to&#xD;
      evaluate long term safety and effectiveness of the SJM™ Masters Series Hemodynamic Plus (HP)&#xD;
      15mm aortic mechanical heart valve (15 AHPJ-505) as a replacement device for pediatric&#xD;
      patients with a diseased, damaged, or malfunctioning aortic valve.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">February 2028</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of total serious valve-related adverse events</measure>
    <time_frame>5 Years</time_frame>
    <description>actuarial (Kaplan-Meier) rate of total serious valve-related adverse events experienced through 5 years post implant or until the valve is removed/replaced. Valve-related adverse events to be evaluated are:&#xD;
Death;&#xD;
Endocarditis;&#xD;
Hemorrhage (whether or not due to anticoagulant/antiplatelet medication);&#xD;
Nonstructural dysfunction (including perivalvular leak, hemolysis, and hemolytic anemia);&#xD;
Reoperation (including valve explant, not due to anatomical growth of the subject);&#xD;
Structural valve deterioration;&#xD;
Thromboembolism&#xD;
Valvular thrombosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak gradient as assessed by echocardiography</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Peak gradient as assessed by echocardiography at 30 Days, 6 Months, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean gradient as assessed by echocardiography</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Mean gradient as assessed by echocardiography at 30 Days, 6 Months, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Valvular regurgitation as assessed by echocardiography</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Valvular regurgitation as assessed by echocardiography at 30 Days, 6 Months, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of all-cause deaths</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of valve-related deaths</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of reoperations or explants excluding replacement due to somatic growth</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <description>Surgical treatment of a diseased, damaged, or malfunctioning aortic valve using SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve surgical replacement device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aortic Valve Replacement</intervention_name>
    <description>SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve as a replacement device for patients with a diseased, damaged, or malfunctioning aortic valve</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This clinical study will enroll male and female subjects from the pediatric population.&#xD;
        Subjects must meet all eligibility criteria and written and signed informed consent must be&#xD;
        obtained from the subject's legal guardian prior to starting the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria for prospectively enrolled subjects&#xD;
&#xD;
               -  Subject's legal guardian must provide written informed consent prior to any&#xD;
                  clinical study related procedure.&#xD;
&#xD;
               -  Subject requires aortic valve replacement and is intended to be implanted with a&#xD;
                  15mm SJM15 AHPJ-505 MHV as determined by the implanting physician in accordance&#xD;
                  with the Instructions for Use.&#xD;
&#xD;
               -  The legal guardian and site agree to follow the subject per the assessment&#xD;
                  schedule and complete all required assessments per this protocol for the duration&#xD;
                  of the clinical study.&#xD;
&#xD;
          -  Inclusion criteria for retrospectively enrolled subjects :&#xD;
&#xD;
        In an effort to ensure data on all real-world use conditions are consistently collected and&#xD;
        reported on, a subject is eligible to participate in this post-approval study if he/she&#xD;
        meets all of the following inclusion criteria and meets no exclusion criterion. For those&#xD;
        subjects with a previous implant attempt to be eligible for study participation, the&#xD;
        following inclusion criteria must be met:&#xD;
&#xD;
          -  Echocardiography data at a time point greater than 90 days is available or may be&#xD;
             acquired.&#xD;
&#xD;
          -  An implant was attempted with the 15mm MHV, where implant attempt is defined as the&#xD;
             device physically contacting the subject's cardiac anatomy.&#xD;
&#xD;
          -  Either:&#xD;
&#xD;
          -  For living subjects who already received the 15mm MHV, the legal guardian signs the&#xD;
             study informed consent for this protocol allowing access to all relevant historical&#xD;
             medical information, and complete all required assessments according to this protocol&#xD;
             from the time of consent going forward (if applicable).&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  For subjects who are deceased or explanted, an implantation with 15mm MHV was&#xD;
             attempted and the subject's legal guardian provides written informed consent for&#xD;
             retrospective data collection of patient and study valve related information through&#xD;
             death or explant of the study device.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria for prospectively enrolled subjects:&#xD;
&#xD;
        Subject has a contraindication to anticoagulant/antiplatelet medication.&#xD;
&#xD;
          -  Exclusion criteria of retrospectively enrolled subjects: None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyle Brunner</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Medical Devices</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Tollefson</last_name>
    <phone>651-756-2438</phone>
    <email>katherine.tollefson@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyle Brunner</last_name>
    <phone>651-756-3482</phone>
    <email>kyle.brunner@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles (USC)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Lemus</last_name>
      <phone>323-361-8656</phone>
      <email>rulemus@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Cynthia Herrington, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Children's Hospital</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Sutter Medical Center, Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Variety Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Guven</last_name>
      <phone>404-785-1403</phone>
      <email>Ashley.guven@choa.org</email>
    </contact>
    <investigator>
      <last_name>Kirk Kanter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalayna Woodly</last_name>
      <phone>513-636-1263</phone>
      <email>shalayna.woodly@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>David Morales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Strelow</last_name>
      <phone>757-238-2691</phone>
      <email>Strelow.Jacob@austin.utexas.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Fraser, Jr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keren Hasbani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Horke</last_name>
      <phone>495115329829</phone>
    </contact>
    <investigator>
      <last_name>Alexander Horke</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samir Sarikouch</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

